#### Check for updates

### OPEN ACCESS

EDITED BY Lia Rimondini, University of Eastern Piedmont, Italy

REVIEWED BY Ksenia Menshikh, Università del Piemonte Orientale, Italy Francesco Baino, Politecnico di Torino, Italy

\*CORRESPONDENCE Meng Wang, wangmeng@hrbmu.edu.cn

<sup>+</sup>These authors have contributed equally to this work

#### SPECIALTY SECTION

This article was submitted to Biomaterials and Bio-Inspired Materials, a section of the journal Frontiers in Materials

RECEIVED 11 July 2022 ACCEPTED 17 August 2022 PUBLISHED 07 September 2022

#### CITATION

Zhang Y, Wu Y, Qiao X, Lin T, Wang Y and Wang M (2022), Biomaterial-based strategy for bone tumor therapy and bone defect regeneration: An innovative application option. *Front. Mater.* 9:990931. doi: 10.3389/fmats.2022.990931

#### COPYRIGHT

© 2022 Zhang, Wu, Qiao, Lin, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Biomaterial-based strategy for bone tumor therapy and bone defect regeneration: An innovative application option

Yue Zhang<sup>1</sup>, Yunjiao Wu<sup>1</sup>, Xinyi Qiao<sup>1</sup>, Tie Lin<sup>2†</sup>, Yicun Wang<sup>3†</sup> and Meng Wang<sup>1\*</sup>

<sup>1</sup>Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China, <sup>2</sup>Department of Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China, <sup>3</sup>Jilin Provincial Key Laboratory on Molecular and Chemical Genetic, The Second Hospital of Jilin University, Changchun, China

Bone tumors are deadly and incurable diseases that invade large areas of bone, resulting in bone defects. Traditional therapies combining surgery, chemotherapy, and radiation have reached their limit of efficacy, motivating efforts to develop new therapeutic methods. Fortunately, the development of biomaterials provides innovative options for bone tumor treatment. Suitable biomaterials are capable of simultaneously providing tumor therapy and promoting bone regeneration. This review summarizes recent progress in the effort to achieve new strategies for bone tumor treatment using biomaterials, focusing on the innovative scaffold design. It also discusses the development of nanocarrier-based drug delivery systems and hyperthermia therapy for bone tumor treatment. In the future, biomaterial-based strategies are likely to become the most effective and reliable options for treating bone tumors, and they have the potential to greatly improve the prognosis and quality of life for patients.


#### KEYWORDS

bone tumor, biomaterial, bone regeneration, drug delivery, hyperthermia therapy

# Introduction

## Epidemiology and clinical background of bone tumor

Bone tumors can be broadly divided into primary bone tumors (sarcomas) and secondary bone tumors (metastases). Primary bone tumors are uncommon (comprising approximately only 0.2% of malignant tumors) in all age groups (Jiang et al., 2020). These tumors are heterogeneous, including osteosarcomas, chondrosarcomas, and Ewing sarcomas, which are mostly diagnosed in childhood and adolescence (Ambrosio et al., 2021). Approximately 30% of patients with primary bone tumors die within 5 years due to poor response to treatment. Metastatic bone tumors are frequent complications of many cancers at a later stage, with a high incidence in breast and prostate cancer in particular. Bone metastasis has a 5-year survival rate of only 10% as a result of poor prognosis (Gonzalez Diaz et al., 2019). Due to their high degree



of malignancy and complexity, strong invasiveness, and considerable mortality, bone tumors bring great suffering to patients.

# Treatment strategies for bone tumor

In the clinic, conventional therapies for bone tumors mainly include surgical interventions, chemotherapy, and radiotherapy. Unfortunately, surgical resection often fails to completely eradicate micrometastases, which is likely to result in postoperative recurrence and metastasis (Chen and Yao, 2022). In some cases, bone defects caused by surgery are the main cause of physical disability. Sometimes, attempts are made to eliminate tumors exclusively with chemotherapy and radiotherapy. However, drug resistance and strong side effects can appear during chemotherapy. Additionally, some bone tumors such as osteosarcoma are not sensitive to radiotherapy and are inclined to chemotherapy resistance (Miwa et al., 2021). Considering the challenges in bone tumor treatment and the clinical need for new approaches, in the last few years, researchers have focused on creating innovative biomaterials with the ability to elicit specific cell behaviors that are needed for both tumor therapy and bone tissue regeneration (Guerrieri et al., 2020).

# Emergence and development of materials for bone repair

In the first attempt of its kind, an American surgeon tried to implant calcium phosphates to repair damaged bone in the early 20th century (Dorozhkin, 2013). Implants designed to repair bone defects have since evolved, with some offering different levels of structural support and some stimulating bone regeneration using osteoinductive materials (Giannoudis et al., 2005). Various materials have been developed over the years, and bone-tissue engineering eventually arose as an independent scientific field in the 1990s (Koons et al., 2020). Bone-tissue engineering has witnessed the rise of some emerging fields, including biomaterial science, developmental and molecular science, and nanotechnology. In the past decade, research in these fields has inspired innovation in new biomaterials, scaffold design, fabrication techniques, and applications. Herein, we review the history of materials for bone repair and provide more details on osteosarcoma treatment, as this field has been dynamically developing due to urgent clinical needs. The timeline of major milestones in the progress of material development for bone repair and osteosarcoma treatment is illustrated in Figure 1.

TABLE 1 Examples of biomaterial scaffolds used in bone tumor therapy and bone regeneration.

| Biomaterial   | <i>In vitro</i><br>model  | In vivo<br>model   | Effect(s)  | Туре                      | References                 |
|---|---|--|--|---------------------------|----------------------------|
| Fe-CaSiO <sub>3</sub> composite scaffolds   | Human osteosarcoma cells<br>(Saos-2)  | Femoral defect models in rabbits                                       | Synergistic photothermal and ROS<br>tumor therapy; the bioactive ions<br>improve osteogenic activity   | Photothermal<br>therapy   | Ma et al. (2018)           |
| Nb <sub>2</sub> C MXer-functionalized scaffolds   | Human osteosarcoma cells<br>(Saos-2)  | Cranial defect model in SD rats  | NIR effect on ablating tumor cells and the ability to promote mineralization   | Photothermal<br>therapy   | Yin et al. (2021)          |
| PLGA/Mg LT-RP 3D-printed scaffolds  | Human osteosarcoma cells<br>(Saos-2)  | Distal femur defect rat<br>model                                       | Photothermal effect to suppress tumor<br>recurrence and the healing process by<br>accelerating bone remodeling                                       | Photothermal<br>therapy   | Long et al.<br>(2021)      |
| Cu-MSN-Tcp scaffolds via spin coating   | Human osteosarcoma cells<br>(MG-63)   |  | Bone tumor cell apoptosis and<br>necrosis by hyperthermia and gene<br>expression of osteogenic markers   | Photothermal<br>therapy   | Ma et al. (2020)           |
| Tricalcium phosphate<br>scaffolds co-loaded with<br>genistein, daidzein and<br>glycitein                        | Human osteosarcoma cells<br>(MG-63)   | Distal femur defect rat<br>model                                       | Localized bone tumor cell suppression<br>and bone cell proliferation   | Drug delivery<br>system   | Sarkar and<br>Bose, (2020) |
| Coloaded Fe <sub>3</sub> O <sub>4</sub> and CaO <sub>2</sub><br>nanoparticle scaffolds                          | MNNG/HOS osteosarcoma<br>tumor cells  | Cranial defects in SD rats   | Useful photothermal therapy for bone tumor   | Photothermal<br>therapy   | Dong et al.<br>(2019)      |
| Hydrogenated black TiO <sub>2</sub><br>coating with biomimetic<br>structures deposited on a<br>titanium implant | Human osteosarcoma cells<br>(Saos-2)  |  | Photothermal ablation to stimulate<br>bone tumor cell necrosis and<br>adhesion; proliferation and osteogenic<br>differentiation of rBMSCs            | Photothermal<br>therapy   | Zhang et al.<br>(2019)     |
| Hydrogel containing cisplatin<br>(DPP) and polydopamine-<br>decorated nano-<br>hydroxyapatite                   | Mouse breast cancer (4T1)<br>cells and human normal<br>breast (MCF-10A) cells       | Tumor model in<br>BALB/c mice  | Synergistic local hyperthermia and<br>drugs to ablate tumors promptly;<br>enhanced bone repair   | Photothermal<br>therapy   | Luo Y. et al.<br>(2019)    |
| A composite scaffold of nano-<br>hydroxyapatite (nHA) and<br>reduced graphene oxide (rGO)                       | Human osteosarcoma cells<br>(MG-63)   | Rat calvaria defect<br>model   | Photothermal effect on killing tumor<br>cells and enhancing bone regeneration<br>in rBMSCs   | Photothermal<br>therapy   | Li L. et al.<br>(2018)     |
| Distributing Fe <sub>3</sub> O <sub>4</sub><br>nanoparticles inside PMMA<br>cement scaffolds                    |   | Tibial plateau bone<br>tumor in rabbits                                | Superior bone tumor ablation upon<br>exposure to an AMF and mechanical<br>support for bone repair  | Magnetothermal<br>therapy | Yu et al. (2019)           |
| Bioactive chitosan (CS) matrix incorporating $Fe_3O_4$ nanoparticles and $GdPO_4$ nanorods                      | MC3T3-E1, RAW264.7 and<br>MDA-MB-231 (breast cancer<br>bone metastasis tumor cells) | Calvarial-defect<br>models in rats and<br>implantation in nude<br>mice | Photothermal ablation to eradicate<br>postoperative residual tumors;<br>nanorod to promote angiogenesis; and<br>osteogenesis for bone defect healing | Photothermal<br>therapy   | Zhao et al.<br>(2020)      |
| SrFe <sub>12</sub> O <sub>19</sub> -modified bioglass<br>(BG)/chitosan (CS) scaffolds                           | Human osteosarcoma cells<br>(MG-63)   | Calvarial-defect<br>models in rats                                     | Magnetothermal therapy in MG-63<br>bone tumors; scaffolds to enhance<br>bone regeneration  | Photothermal<br>therapy   | Lu et al. (2018)           |
| CuFeSe <sub>2</sub> -functionalized BG<br>scaffolds   | Human osteosarcoma cells<br>(Saos-2)  | Femoral defect models in rabbits                                       | Metal elements in BG to endow BG<br>with both photothermal effect and<br>bone regeneration ability   | Photothermal<br>therapy   | Dang et al.<br>(2018)      |

ROS, reactive oxygen species; Nb<sub>2</sub>C, 2D niobium carbide; SD, Sprague–Dawle; NIR, near-infrared; PLGA, poly(lactide-co-glycolide); LT-PR, low temperature rapid prototyping; 3D, threedimension; MSN, mesoporous silica nanosphere; Tcp, tricalcium phosphate; rBMSCs, rat bone marrow stem cells; PMMA, polymethylmethacrylate; AMF, alternating magnetic field.

# A new strategy for bone tumor therapy and bone regeneration

The two main challenges in bone tumor therapy are eliminating tumor cells and facilitating bone regeneration (Ma et al., 2018; Liao et al., 2021). Some new therapies have shown strong potential, particularly the biomaterial-based strategy (including targeted drug delivery and hyperthermia therapy), which has demonstrated high anticancer effects (Tan et al., 2021). More importantly, biomaterial scaffolds can provide an ideal *in*  *vivo* environment for cells to grow, proliferate, and differentiate, and they can also leverage the synergistic effect of bioactive molecules for bone tissue repair (Brunello et al., 2020; Tan et al., 2021). Thus, the biomaterial-based strategy is an innovative option that is capable of simultaneously achieving bone tumor therapy and promoting bone regeneration.

In this review, we summarize the recent progress in the development of biomaterials for bone tumor therapy and bone defect regeneration. We describe biomaterial scaffolds created for simultaneous bone tumor therapy and bone regeneration, focusing on innovative scaffold design. Finally, we also discuss nanocarrier-based drug delivery systems and hyperthermia therapy for bone tumor treatment.

# Role of scaffolds

When treating bone defects caused by tumor resection, the design of biomaterials must simultaneously meet the requirements of bone repair and tumor suppression. Therefore, biomaterial selection and structural design are critical (Du et al., 2019). The purpose of a biomaterial scaffold is not to simply replace the missing bone tissue but also to create a biomimetic microenvironment for the growth of cells and tissues by mimicking the natural extracellular matrix. The scaffold must inherit the biomaterial's advantageous properties, such as excellent biocompatibility, adequate mechanical strength, biodegradation, and cell adhesion and transportation (Tevlin et al., 2014).

# Types of scaffolds

Biomaterials used in scaffolds can be divided into polymers, bioceramics, carbon containing materials, metals, and hydrogels (Marques et al., 2014). Table 1 shows bioactive scaffolds fabricated for bone tumor treatment and bone regeneration.

## Polymers

Polymeric materials have strong potential for application in bone tumor therapy due to their good biocompatibility and design flexibility. According to their origin, polymers can be simply classified into two groups, namely natural polymers and synthetic polymers (Filippi et al., 2020).

Natural polymers used for bone tissue regeneration mainly include collagen, gelatin, chitosan, and alginate (Marques et al., 2014; Zhao et al., 2020). They are similar to the components in the native extracellular matrix, ensuring superior biocompatibility and minute immunogenicity. One potential advantage of natural polymers is that they often contain functional molecules, which is advantageous for cellular adhesion (Bose et al., 2012). However, natural polymers also face many disadvantages. In some cases, pathogenic impurities may exist, which can trigger immunogenic reactions. Other disadvantages include low mechanical strength, poor elastic properties, and less control over degradability, which could limit their use in load-bearing applications (Peric Kacarevic et al., 2020).

Synthetic polymers such as polymethylmethacrylate (PMMA) and poly (lactic-coglycolic acid) (PLGA) have been investigated for bone tumor applications (Yu et al., 2019; Long et al., 2021). Unlike natural polymers, synthetic polymers can be fabricated to meet desired mechanical characteristics and geometric properties. However, poor biocompatibility and

unsatisfactory hydrophilicity limit clinical applications of synthetic polymers. Furthermore, synthetic polymers produce undesirable degradation products and create a local acidic environment, which can have cytotoxic effects and cause inflammatory responses (Bharadwaz and Jayasuriya, 2020).

# **Bioceramics**

Calcium phosphate ceramics, including hydroxyapatite (HA), βtricalcium phosphate, and bioactive glass (BG), are commonly used for orthopedic applications, as calcium phosphate is abundant in native human bone (Luo S. et al., 2019; Dang et al., 2018; Lu et al., 2018; H. Ma et al., 2020). Hydroxyapatite is present in natural bone as an inorganic component of bone matrix. It has excellent biocompatibility and osteoinduction properties, so it has been widely used in bone defect repair materials and has also been considered as a promising carrier for drug delivery to sites of bone disease (Marques et al., 2014; Tang et al., 2021). Hydroxyapatite could allow strong integration with host tissue, further promoting new bone formation in vivo and selectively and efficiently killing tumor cells in vitro to achieve the purpose of bone tumor therapy (Luo Y. et al., 2019). The design of bioceramics not only greatly expands bone tumor therapeutic strategies but also represents a new direction for bioceramics science. However, the drawback of brittleness could limit the utility of bioceramics in load-bearing support. Additionally, it is difficult to tune the resorption rate of bioceramics, resulting in a decline of mechanical properties (Turnbull et al., 2018).

## Metals

Generally, an ideal metallic material possesses excellent biocompatibility and high mechanical performance, and it releases non-toxic ions. As typical representatives, magnesium (Mg), titanium, and their alloys are suitable for clinical applications (Huang et al., 2020). However, poor corrosion resistance could induce tissue reactions and raise the risk of loosening. The higher elastic modulus of metals relative to natural bone can also result in bone resorption and therapeutic failure. In addition, poor biodegradability may lead to further impairment of tissue ingrowth (Turnbull et al., 2018). However, surface modification has been applied to improve bioactivity in traditional biomaterials. It enhances metallic corrosion resistance and promotes osteoblast attachment through coating, showing superior osteogenesis and integration ability (Zhang et al., 2019).

# Carbon and other nanoparticles

It is well known that scaffolds have been significantly improved using nanobiological materials (Quadros et al.,

| Nanoparticle type                   | Drug carrier   | Chemotherapeutic drugs      | References                    |
|-------------------------------------|--|-----------------------------|-------------------------------|
| Polymeric nanoparticles             | Coupling of Methotrexate with PGA nanoparticles                    | Methotrexate                | Suksiriworapong et al. (2018) |
| Polymeric nanoparticles             | Keratin nanoparticles functionalized by Chlorin-e6                 | Paclitaxel                  | Martella et al. (2018)        |
| Polymeric nanoparticles             | PLGA nanoparticles   | Salinomycin                 | Irmak et al. (2020)           |
| Polymeric nanoparticles             | Poly (ester amide)   | Apatinib                    | Li et al. (2020b)             |
| Polymeric nanoparticles             | Poloxamers modified with trimethyl chitosan                        | Methotrexate                | Li et al. (2017)              |
| Polymeric micelles                  | HA-octadecanoic acid (contains alendronate)                        | Curcumin                    | Xi et al. (2019)              |
| Polymeric micelles                  | Bone-targeting micelles (contains D-aspartic acid octapeptide)     | Doxorubicin                 | Low et al. (2014)             |
| Polymeric micelles                  | Micelles with RGD-modified   | Doxorubicin                 | Fang et al. (2017)            |
|                                     | PEG-block-poly (trimethylene carbonate) copolymer                  |                             |                               |
| Polymeric nanogels                  | HA-based nanogels  | Cisplatin and Doxorubicin   | Zhang et al. (2018)           |
| Metallic nanoparticles              | Fe <sub>3</sub> O <sub>4</sub> -based nanoparticles                | Gemcitabine                 | Popescu et al. (2017)         |
| Mesoporous silica nanoparticles     | PEI-modified and iron oxide-loaded mesoporous silica nanoparticles | Doxorubicin                 | Hartono et al. (2014)         |
| Carbon nanomaterials                | (TRA/GO nano-complexes)  | Trastuzumab                 | Li D. et al. (2018)           |
| Calcium phosphates<br>nanoparticles | Bisphosphonate modified HANPs                                      | JQ1                         | Wu et al. (2017)              |
| Liposomes                           | COS modified liposomes   | Doxorubicin                 | Yin et al. (2017)             |
| Liposomes                           | PEGylated liposomes  | Gemcitabine and Clofazimine | Caliskan et al. (2019)        |
| Liposomes                           | PEGylated liposomes coated with gold nanoshells                    | Betulinic acid              | Liu et al. (2017)             |
| Liposomes                           | Liposomes modified with alendronic acid and LMWH                   | Doxorubicin                 | Wu et al. (2020)              |

TABLE 2 Drug delivery systems developed for the treatment of osteosarcoma.

PGA, poly glycerol adipate; PLGA, poly lactideco-glycolic acid; HA, hyaluronic acid; RGD, arginine-glycine-aspartic peptide acid; PEI, polyethyleneimine; HANPs, hydroxyapatite nanoparticles; TRA, trastuzumab; GO, graphene oxide; JQ1, a small-molecule bromodomain inhibitor; COS, chitooligosaccharides; PEG, polyethylene glycol; LMWH, low molecular weight heparin.

2021). Nanomaterials, including polymeric nanoparticles, carbon-based nanomaterials, and metallic nanoparticles, have been designed to permit local drug delivery in bone tumor therapies. They also have excellent photothermal conversion ability and high adsorption ability, so they could serve as photothermal agents (Badila et al., 2021).

Carbon-based materials are potentially useful nanomaterials for bone tumor treatment. Most studied carbon materials for therapeutics are graphene, graphene oxide (GO), and reduced graphene oxide (rGO) (Li D. et al., 2018; Yin et al., 2021). Both GO and rGO are generated through graphene conversion (Geetha Bai et al., 2019). Graphene has exceptional mechanical properties, favorable osteoinductivity, and a large surface area. It can provide active sites that support cell differentiation, growth, and proliferation. However, the cytotoxicity of graphene and its derivatives has always been problematic (Fang et al., 2022).


With the development of biomaterial science, inorganic nanoparticles have also made their way into therapeutics through the use of nanotechnology (Fang et al., 2022). Metal nanoparticles such as Fe and Cu, which have been incorporated into scaffolds, have shown potential in promoting the proliferation and differentiation of mesenchymal stem cells (MSCs) in animal models (Dang et al., 2018; Lu et al., 2018; Ma et al., 2018).

## **Hydrogels**

Hydrogels biocompatibility, possess good biodegradability, injectability, and the ability to load growth factors, meaning they have the potential to repair bone defects (Fang et al., 2022). Some new injectable hydrogels prepared through chemical reactions have been applied to bone tumor treatment. They not only effectively ablate bone tumor cells via photothermal effects but also support the attachment, proliferation, and osteogenic differentiation of bone MSCs. In addition, they can be used for more accurate targeted delivery of anticancer drugs and fixation of bone defect tissue (Yu and Ding, 2008; Luo S. et al., 2019). Although hydrogels are still in development, the prospect of multifunctional hydrogel-based materials has been strongly demonstrated in anticancer treatment and bone repair.

# Enhancing regenerative capacity of biomaterials: Seed cells and growth factors

To engineer the ideal biomaterial scaffold, osteoinductive bioactive components, such as growth factors and progenitor



cells, should be successfully recruited for bone regeneration (Qi et al., 2021). The essential stem cell sources provide higher proliferative ability and allow the differentiation of various cell types from a single cell (Vats et al., 2002). MSCs, endothelial progenitor cells (EPCs), and induced pluripotent stem cells (iPSCs) are included in bone progenitor cells. MSCs are currently more suitable for tissue repair since they can differentiate into bone and connective tissues (Vats et al., 2002). The incorporation of growth factors into biomaterial scaffolds can promote cell growth and differentiation for the normal healing response. Growth factors for improving osteogenesis and angiogenesis include vascular endothelial growth factors (VEGF), fibroblast growth factors (FGFs), and bone morphogenic proteins (BMPs) (Brunello et al., 2020; Qi et al., 2021).

# Fabrication of Scaffolds-3D printing technology

The development and application of 3D printing technology represents a huge opportunity for bone-tissue engineering. Over the years, this technology has quickly evolved into advanced methods suitable for the fabrication of novel, geometrically intricate, biomimetic biomaterial scaffolds (Nikolova and Chavali, 2019). Moreover, 3D printing technology can be used to design and manufacture living tissue-like structures with properties similar to those of natural bone tissue (Parisi et al., 2018). Additionally, computer-assisted design technologies can be used to generate 3D models that fully resemble native tissue to better mimic cellular interactions and processes (Vats et al., 2002; Koons et al., 2020). Overall, 3D printing is regarded as a revolutionary and powerful tool that has been successfully employed in medicine, especially in the field of tissue engineering. However, it still faces great challenges, and solving these challenges will require multidisciplinary collaboration on the creation of advanced techniques for analysis and quantification.

# Nanocarrier-based drug delivery systems and hyperthermia therapy

As one of the widely investigated applications for nanotechnology, nanocarrier-based drug delivery systems offer promise for the treatment of cancers (Bae et al., 2011). Nanomaterials can be used as carriers to encapsulate chemotherapeutic agents to prolong drug circulation time and protect them from rapid clearance (Muntimadugu et al., 2017). Targeting the delivery of drugs to the bone could achieve a high local concentration, enhance therapeutic efficiency, and reduce systemic toxicity (Bae et al., 2011; Lungu et al., 2019). The successful exploration of drug delivery systems will provide new methods for ideal bone tumor therapy, which encourages the development of targeted therapies. Nanocarriers developed for bone tumor mainly include liposomes, polymeric nanoparticles, metallic nanoparticles, carbon-based nanomaterials, and calcium phosphate carriers (Wang et al., 2020). Table 2 summarizes the application of antineoplastic drugs and nanocarriers in osteosarcoma drug delivery systems.

Studies on hyperthermia therapy, such as biomaterials with good photothermal and magnetothermal properties, have demonstrated encouraging outcomes in bone tumor treatment. Photothermal therapy (PTT) employs near-infrared (NIR) laser photoabsorbers to convert light energy into heat energy to ablate cancer cells (Zou et al., 2016; de Oliveira et al., 2021). Photothermal agents could be used as NIR absorbents and enhancers to increase the efficiency of localized light-based heating (Li et al., 2020a). To date, various types of photothermal agents using biomaterials, such as metal nanomaterials, carbon-based nanoparticles, and biomaterial scaffolds, have been designed and developed for bone tumor treatment (Zou et al., 2016). Photodynamic therapy (PDT) can also selectively induce the death of tumor cells, which is based on the localized generation of oxidative stress, preserving normal tissues (Sibata et al., 2000). It has been proved that giant cell tumors, chondrosarcoma, and osteosarcoma are susceptible to in vitro PDT (Hourigan et al., 1993). Magnetic hyperthermia (MHT) is a non-invasive method for bone tumor ablation, and it is based on heat generation by magnetic materials (Sedighi et al., 2021). MHT could achieve localized tumor heating and induces the apoptosis/necrosis of cells by the transformation of electromagnetic energy under an alternating magnetic field (Fatima et al., 2021).

# Conclusion and prospects

With the development of material science, biomaterials have attracted increasing attention due to their specific biological properties, excellent tumor specificity, and high drug-loading capacity. One of the major advantages of biomaterials is how precisely they can be controlled with specific structures according to individual defect conditions. Biomaterial scaffolds largely mimic native tissue, with excellent biosafety and minimal biological immune reactions due to the combination of biomaterials and bioactive components, allowing them to be used safely in patients. In recent decades, researchers have attempted to design functional biomaterials for simultaneously killing bone tumor cells and repairing bone defects induced by surgical resection. In addition, multifunctional biomaterial designs enabling bone regeneration, chemotherapy drug delivery, and the anticancer effects of hyperthermia therapy have been constructed. Thus, supplementary or alternative methods based on biomaterials are expected to become integrated bone tumor therapy strategies (Figure 2).

Although many studies have shown that hyperthermia could effectively result in irreversible cell death and tumor destruction by generating high temperatures, it is difficult to avoid damage to normal tissue and other side effects, such as local immuneinflammatory response. Recently, more efficient drug delivery systems incorporating bioactive substances (antibiotics or antineoplastic drugs) have been designed through biomaterial modification, allowing drugs to be released *in situ* (Andronescu et al., 2013). However, the precise control of drug distribution in space and time is a challenge still faced by drug delivery systems, so further studies are needed. Last but not least, it should be kept in mind that multiple functions of biomaterials are based on animal model studies. We believe that through the interdisciplinary collaboration of experts in the fields of clinical medicine, material science, and nanotechnology, more detailed studies and comprehensive explorations can successfully identify treatments with higher efficiency to aid in the fight against bone tumors.

This review summarizes the very latest developments in the biomaterial-based strategy for bone tumor treatment, with a focus on innovative scaffold design. It also discusses nanomaterials that can help deliver drugs or provide hyperthermia therapy to kill bone tumor cells. In the future, the biomaterial-based strategy may offer unprecedented opportunities for clinical bone tumor therapy and bone regeneration while reducing treatment periods and ultimately improving the prognosis of patients.

# Author contributions

YZ reviewed the literature, and wrote the manuscript. YW and XQ wrote and revised the manuscript. TL and YW assisted in drawing. MW designed and revised the manuscript. All authors contributed to the article and approved the submitted version.

# Funding

This work was supported by Grants from the Natural Science Foundation of Heilongjiang Province (No. LH2019H039), and the Haiyan Foundation of Harbin Medical University Cancer Hospital (No. JJZD2020-09).

# Acknowledgments

We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript.

# Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

#### 10.3389/fmats.2022.990931

# References

Ambrosio, L., Raucci, M. G., Vadala, G., Ambrosio, L., Papalia, R., and Denaro, V. (2021). Innovative biomaterials for the treatment of bone cancer. *Int. J. Mol. Sci.* 22 (15), 8214. doi:10.3390/ijms22158214

Andronescu, E., Ficai, A., Albu, M. G., Mitran, V., Sonmez, M., Ficai, D., et al. (2013). Collagen-hydroxyapatite/cisplatin drug delivery systems for locoregional treatment of bone cancer. *Technol. Cancer Res. Treat.* 12 (4), 275–284. doi:10.7785/tcrt.2012.500331

Badila, A. E., Radulescu, D. M., Niculescu, A. G., Grumezescu, A. M., Radulescu, M., and Radulescu, A. R. (2021). Recent advances in the treatment of bone metastases and primary bone tumors: An up-to-date review. *Cancers (Basel)* 13 (16), 4229. doi:10.3390/cancers13164229

Bae, K. H., Chung, H. J., and Park, T. G. (2011). Nanomaterials for cancer therapy and imaging. *Mol. Cells* 31 (4), 295–302. doi:10.1007/s10059-011-0051-5

Bharadwaz, A., and Jayasuriya, A. C. (2020). Recent trends in the application of widely used natural and synthetic polymer nanocomposites in bone tissue regeneration. *Mater. Sci. Eng. C* 110, 110698. doi:10.1016/j.msec.2020.110698

Bose, S., Roy, M., and Bandyopadhyay, A. (2012). Recent advances in bone tissue engineering scaffolds. *Trends Biotechnol.* 30 (10), 546–554. doi:10.1016/j.tibtech. 2012.07.005

Brunello, G., Panda, S., Schiavon, L., Sivolella, S., Biasetto, L., and Del Fabbro, M. (2020). The impact of bioceramic scaffolds on bone regeneration in preclinical *in vivo* studies: A systematic review. *Mater. (Basel)* 13 (7), 1500. doi:10.3390/ma13071500

Caliskan, Y., Dalgic, A. D., Gerekci, S., Gulec, E. A., Tezcaner, A., Ozen, C., et al. (2019). A new therapeutic combination for osteosarcoma: Gemcitabine and Clofazimine co-loaded liposomal formulation. *Int. J. Pharm. X.* 557, 97–104. doi:10.1016/j.ijpharm.2018.12.041

Chen, H., and Yao, Y. (2022). Progress of biomaterials for bone tumor therapy. J. Biomater. Appl. 36 (6), 945–955. doi:10.1177/08853282211035236

Dang, W., Li, T., Li, B., Ma, H., Zhai, D., Wang, X., et al. (2018). A bifunctional scaffold with CuFeSe<sub>2</sub> nanocrystals for tumor therapy and bone reconstruction. *Biomaterials* 160, 92–106. doi:10.1016/j.biomaterials.2017.11.020

de Oliveira, S. A., Borges, R., Dos Santos Rosa, D., de Souza, A. C. S., Seabra, A. B., Baino, F., et al. (2021). Strategies for cancer treatment based on photonic nanomedicine. *Mater. (Basel)* 14 (6), 1435. doi:10.3390/ma14061435

Dong, S., Chen, Y., Yu, L., Lin, K., and Wang, X. (2019). Magnetic hyperthermiasynergistic  $H_2O_2$  self-sufficient catalytic suppression of osteosarcoma with enhanced bone-RegenerationBioactivity by 3D-printing composite scaffolds. *Adv. Funct. Mat.* 30 (4), 1907071. doi:10.1002/adfm.201907071

Dorozhkin, S. V. (2013). A detailed history of calcium orthophosphates from 1770s till 1950. *Mater. Sci. Eng. C* 33 (6), 3085–3110. doi:10.1016/j.msec.2013. 04.002

Du, Y., Guo, J. L., Wang, J., Mikos, A. G., and Zhang, S. (2019). Hierarchically designed bone scaffolds: From internal cues to external stimuli. *Biomaterials* 218, 119334. doi:10.1016/j.biomaterials.2019.119334

Fang, H., Zhu, D., Yang, Q., Chen, Y., Zhang, C., Gao, J., et al. (2022). Emerging zero-dimensional to four-dimensional biomaterials for bone regeneration. *J. Nanobiotechnol.* 20 (1), 26. doi:10.1186/s12951-021-01228-1

Fang, Z., Sun, Y., Xiao, H., Li, P., Liu, M., Ding, F., et al. (2017). Targeted osteosarcoma chemotherapy using RGD peptide-installed doxorubicin-loaded biodegradable polymeric micelle. *Biomed. Pharmacother.* 85, 160–168. doi:10. 1016/j.biopha.2016.11.132

Fatima, H., Charinpanitkul, T., and Kim, K. S. (2021). Fundamentals to apply magnetic nanoparticles for hyperthermia therapy. *Nanomater. (Basel)* 11 (5), 1203. doi:10.3390/nano11051203

Filippi, M., Born, G., Chaaban, M., and Scherberich, A. (2020). Natural polymeric scaffolds inBone regeneration. *Front. Bioeng. Biotechnol.* 8, 474. doi:10.3389/fbioe. 2020.00474

Geetha Bai, R., Muthoosamy, K., Manickam, S., and Hilal-Alnaqbi, A. (2019). Graphene-based 3D scaffolds in tissue engineering: Fabrication, applications, and future scope in liver tissue engineering. *Int. J. Nanomedicine* 14, 5753–5783. doi:10. 2147/iin.S192779

Giannoudis, P. V., Dinopoulos, H., and Tsiridis, E. (2005). Bone substitutes: An update. *Injury* 36 (3), S20–S27. doi:10.1016/j.injury.2005.07.029

Gonzalez Diaz, E. C., Sinha, S., Avedian, R. S., and Yang, F. (2019). Tissueengineered 3D models for elucidating primary and metastatic bone cancer progression. *Acta Biomater.* 99, 18–32. doi:10.1016/j.actbio.2019.08.020

Guerrieri, A. N., Montesi, M., Sprio, S., Laranga, R., Mercatali, L., Tampieri, A., et al. (2020). Innovative options for bone metastasis treatment: An extensive

analysis on biomaterials-based strategies for orthopedic surgeons. Front. Bioeng. Biotechnol. 8, 589964. doi:10.3389/fbioe.2020.589964

Hartono, S. B., Yu, M., Gu, W., Yang, J., Strounina, E., Wang, X., et al. (2014). Synthesis of multi-functional large pore mesoporous silica nanoparticles as gene carriers. *Nanotechnology* 25 (5), 055701. doi:10.1088/0957-4484/25/5/ 055701

Hourigan, A. J., Kells, A. F., and Schwartz, H. S. (1993). *In vitro* photodynamic therapy of musculoskeletal neoplasms. *J. Orthop. Res.* 11 (5), 633–637. doi:10.1002/jor.1100110504

Huang, S., Wang, B., Zhang, X., Lu, F., Wang, Z., Tian, S., et al. (2020). Highpurity weight-bearing magnesium screw: Translational application in the healing of femoral neck fracture. *Biomaterials* 238, 119829. doi:10.1016/j.biomaterials.2020. 119829

Irmak, G., Öztürk, M. G., and Gümüşderelioğlu, M. (2020). Salinomycin encapsulated PLGA nanoparticles eliminate osteosarcoma cells via inducing/ inhibiting multiple signaling pathways: Comparison with free salinomycin. J. Drug Deliv. Sci. Technol. 58, 101834. doi:10.1016/j.jddst.2020.101834

Jiang, W., Rixiati, Y., Zhao, B., Li, Y., Tang, C., and Liu, J. (2020). Incidence, prevalence, and outcomes of systemic malignancy with bone metastases. *J. Orthop. Surg. Hong. Kong*) 28 (2), 230949902091598. doi:10.1177/2309499020915989

Koons, G. L., Diba, M., and Mikos, A. G. (2020). Materials design for bone-tissue engineering. *Nat. Rev. Mat.* 5 (8), 584–603. doi:10.1038/s41578-020-0204-2

Li, D., Nie, W., Chen, L., McCoul, D., Liu, D., Zhang, X., et al. (2018). Self-assembled hydroxyapatite-graphene scaffold for photothermal cancer therapy and bone regeneration. *J. Biomed. Nanotechnol.* 14 (12), 2003–2017. doi:10.1166/jbn.2018.2646

Li, L., Luo, C., Song, Z., Reyes-Vargas, E., Clayton, F., Huang, J., et al. (2018). Association of anti-HER2 antibody with graphene oxide for curative treatment of osteosarcoma. *Nanomedicine Nanotechnol. Biol. Med.* 14 (2), 581–593. doi:10.1016/ j.nano.2017.11.001

Li, S., Xiong, Y., and Zhang, X. (2017). Poloxamer surface modified trimethyl chitosan nanoparticles for the effective delivery of methotrexate in osteosarcoma. *Biomed. Pharmacother.* 90, 872–879. doi:10.1016/j.biopha.2017.04.004

Li, X., Park, E. Y., Kang, Y., Kwon, N., Yang, M., Lee, S., et al. (2020a). Supramolecular phthalocyanine assemblies for improved photoacoustic imaging and photothermal therapy. *Angew. Chem. Int. Ed.* 59 (22), 8630–8634. doi:10.1002/ anie.201916147

Li, X., Wang, L., Wang, L., Yu, J., Lu, G., Zhao, W., et al. (2020b). Overcoming therapeutic failure in osteosarcoma via Apatinib-encapsulated hydrophobic poly(ester amide) nanoparticles. *Biomater. Sci.* 8 (21), 5888–5899. doi:10.1039/d0bm01296c

Liao, J., Han, R., Wu, Y., and Qian, Z. (2021). Review of a new bone tumor therapy strategy based on bifunctional biomaterials. *Bone Res.* 9 (1), 18. doi:10.1038/s41413-021-00139-z

Liu, Y., Zhang, X., Liu, Z., Wang, L., Luo, L., Wang, M., et al. (2017). Gold nanoshell-based betulinic acid liposomes for synergistic chemo-photothermal therapy. *Nanomedicine Nanotechnol. Biol. Med.* 13 (6), 1891–1900. doi:10.1016/j.nano.2017.03.012

Long, J., Zhang, W., Chen, Y., Teng, B., Liu, B., Li, H., et al. (2021). Multifunctional magnesium incorporated scaffolds by 3D-Printing for comprehensive postsurgical management of osteosarcoma. *Biomaterials* 275, 120950. doi:10.1016/j.biomaterials.2021.120950

Low, S. A., Yang, J., and Kopecek, J. (2014). Bone-targeted acid-sensitive doxorubicin conjugate micelles as potential osteosarcoma therapeutics. *Bioconjug. Chem.* 25 (11), 2012–2020. doi:10.1021/bc500392x

Lu, J. W., Yang, F., Ke, Q. F., Xie, X. T., and Guo, Y. P. (2018). Magnetic nanoparticles modified-porous scaffolds for bone regeneration and photothermal therapy against tumors. *Nanomedicine Nanotechnol. Biol. Med.* 14 (3), 811–822. doi:10.1016/j.nano.2017.12.025

LunguII, Grumezescu, A. M., Volceanov, A., and Andronescu, E. (2019). Nanobiomaterials used in cancer therapy: An up-to-date overview. *Molecules* 24 (19), 3547. doi:10.3390/molecules24193547

Luo, S., Wu, J., Jia, Z., Tang, P., Sheng, J., Xie, C., et al. (2019). An injectable, bifunctional hydrogel with photothermal effects for tumor therapy and bone regeneration. *Macromol. Biosci.* 19 (9), e1900047. doi:10.1002/mabi.201900047

Luo, Y., Wei, X., Wan, Y., Lin, X., Wang, Z., and Huang, P. (2019). 3D printing of hydrogel scaffolds for future application in photothermal therapy of breast cancer and tissue repair. *Acta Biomater*. 92, 37–47. doi:10.1016/j.actbio.2019.05.039

Ma, H., Li, T., Huan, Z., Zhang, M., Yang, Z., Wang, J., et al. (2018). 3D printing of high-strength bioscaffolds for the synergistic treatment of bone cancer. *NPG Asia Mat.* 10 (4), 31–44. doi:10.1038/s41427-018-0015-8

Ma, H., Ma, Z., Chen, Q., Li, W., Liu, X., Ma, X., et al. (2020). Bifunctional, copper-doped, mesoporous silica nanosphere-modified, bioceramic scaffolds for bone tumor therapy. *Front. Chem.* 8, 610232. doi:10.3389/fchem.2020. 610232

Marques, C., Ferreira, J. M., Andronescu, E., Ficai, D., Sonmez, M., and Ficai, A. (2014). Multifunctional materials for bone cancer treatment. *Int. J. Nanomedicine* 9, 2713–2725. doi:10.2147/IJN.S55943

Martella, E., Ferroni, C., Guerrini, A., Ballestri, M., Columbaro, M., Santi, S., et al. (2018). Functionalized keratin as nanotechnology-based drug delivery system for the pharmacological treatment of osteosarcoma. *Int. J. Mol. Sci.* 19 (11), 3670. doi:10.3390/ijms19113670

Miwa, S., Yamamoto, N., and Tsuchiya, H. (2021). Bone and soft tissue tumors: New treatment approaches. *Cancers (Basel)* 13 (8), 1832. doi:10.3390/cancers13081832

Muntimadugu, E., Kommineni, N., and Khan, W. (2017). Exploring the potential of nanotherapeutics in targeting tumor microenvironment for cancer therapy. *Pharmacol. Res.* 126, 109–122. doi:10.1016/j.phrs.2017.05.010

Nikolova, M. P., and Chavali, M. S. (2019). Recent advances in biomaterials for 3D scaffolds: A review. *Bioact. Mat.* 4, 271–292. doi:10.1016/j.bioactmat.2019.10.005

Parisi, L., Toffoli, A., Ghiacci, G., and Macaluso, G. M. (2018). Tailoring the interface of biomaterials to design effective scaffolds. *J. Funct. Biomater.* 9 (3), 50. doi:10.3390/jfb9030050

Peric Kacarevic, Z., Rider, P., Alkildani, S., Retnasingh, S., Pejakic, M., Schnettler, R., et al. (2020). An introduction to bone tissue engineering. *Int. J. Artif. Organs* 43 (2), 69–86. doi:10.1177/0391398819876286

Popescu, R. C., Andronescu, E., Vasile, B. S., Trusca, R., Boldeiu, A., Mogoanta, L., et al. (2017). Fabrication and cytotoxicity of gemcitabine-functionalized magnetite nanoparticles. *Molecules* 22 (7), 1080. doi:10.3390/molecules22071080

Qi, J., Yu, T., Hu, B., Wu, H., and Ouyang, H. (2021). Current biomaterial-based bone TissueEngineering and translational medicine. *Int. J. Mol. Sci.* 22 (19), 10233. doi:10.3390/ijms221910233

Quadros, M., Momin, M., and Verma, G. (2021). Design strategies and evolving role of biomaterial assisted treatment of osteosarcoma. *Mater. Sci. Eng. C* 121, 111875. doi:10.1016/j.msec.2021.111875

Sarkar, N., and Bose, S. (2020). Controlled release of soy isoflavones from multifunctional 3D printed bone tissue engineering scaffolds. *Acta Biomater.* 114, 407–420. doi:10.1016/j.actbio.2020.07.006

Sedighi, O., Alaghmandfard, A., Montazerian, M., and Baino, F. (2021). A critical review of bioceramics for magnetic hyperthermia. *J. Am. Ceram. Soc.* 105, 1723–1747. doi:10.1111/jace.17861

Sibata, C. H., Colussi, V. C., Oleinick, N. L., and Kinsella, T. J. (2000). Photodynamic therapy: A new concept in medical treatment. *Braz. J. Med. Biol. Res.* 33 (8), 869–880. doi:10.1590/s0100-879x200000800002

Suksiriworapong, J., Taresco, V., Ivanov, D. P., Styliari, I. D., Sakchaisri, K., Junyaprasert, V. B., et al. (2018). Synthesis and properties of a biodegradable polymer-drug conjugate: Methotrexate-poly(glycerol adipate). *Colloids Surfaces B Biointerfaces* 167, 115–125. doi:10.1016/j.colsurfb.2018.03.048

Tan, B., Tang, Q., Zhong, Y., Wei, Y., He, L., Wu, Y., et al. (2021). Biomaterialbased strategies for maxillofacial tumour therapy and bone defect regeneration. *Int. J. Oral Sci.* 13 (1), 9. doi:10.1038/s41368-021-00113-9

Tang, G., Liu, Z., Liu, Y., Yu, J., Wang, X., Tan, Z., et al. (2021). Recent trends in the development of bone regenerative biomaterials. *Front. Cell Dev. Biol.* 9, 665813. doi:10.3389/fcell.2021.665813

Tevlin, R., McArdle, A., Atashroo, D., Walmsley, G. G., Senarath-Yapa, K., Zielins, E. R., et al. (2014). Biomaterials for craniofacial bone engineering. *J. Dent. Res.* 93 (12), 1187–1195. doi:10.1177/0022034514547271

Turnbull, G., Clarke, J., Picard, F., Riches, P., Jia, L., Han, F., et al. (2018). 3D bioactive composite scaffolds for bone tissue engineering. *Bioact. Mat.* 3 (3), 278–314. doi:10.1016/j.bioactmat.2017.10.001

Vats, A., Tolley, N. S., Polak, J. M., and Buttery, L. D. (2002). Stem cells: Sources and applications. *Clin. Otolaryngol.* 27 (4), 227–232. doi:10.1046/j.1365-2273.2002. 00579.x

Wang, S. Y., Hu, H. Z., Qing, X. C., Zhang, Z. C., and Shao, Z. W. (2020). Recent advances of drug delivery nanocarriers in osteosarcoma treatment. *J. Cancer* 11 (1), 69–82. doi:10.7150/jca.36588

Wu, H., Luo, Y., Xu, D., Ke, X., and Ci, T. (2020). Low molecular weight heparin modified bone targeting liposomes for orthotopic osteosarcoma and breast cancer bone metastatic tumors. *Int. J. Biol. Macromol.* 164, 2583–2597. doi:10.1016/j. ijbiomac.2020.08.068

Wu, V. M., Mickens, J., and Uskokovic, V. (2017). Bisphosphonate-functionalized hydroxyapatite nanoparticles for the delivery of the bromodomain inhibitor JQ1 in the treatment of osteosarcoma. *ACS Appl. Mat. Interfaces* 9 (31), 25887–25904. doi:10.1021/acsami.7b08108

Xi, Y., Jiang, T., Yu, Y., Yu, J., Xue, M., Xu, N., et al. (2019). Dual targeting curcumin loaded alendronate-hyaluronan- octadecanoic acid micelles for improving osteosarcoma therapy. *Int. J. Nanomedicine* 14, 6425–6437. doi:10. 2147/IJN.S211981

Yin, J., Pan, S., Guo, X., Gao, Y., Zhu, D., Yang, Q., et al. (2021). Nb<sub>2</sub>C MXenefunctionalized scaffolds enables osteosarcoma phototherapy and angiogenesis/ osteogenesis of bone defects. *Nanomicro. Lett.* 13 (1), 30. doi:10.1007/s40820-020-00547-6

Yin, X., Chi, Y., Guo, C., Feng, S., Liu, J., Sun, K., et al. (2017). Chitooligosaccharides modified reduction-sensitive liposomes: Enhanced cytoplasmic drug delivery and osteosarcomas-tumor inhibition in animal models. *Pharm. Res.* 34 (10), 2172–2184. doi:10.1007/s11095-017-2225-0

Yu, K., Liang, B., Zheng, Y., Exner, A., Kolios, M., Xu, T., et al. (2019). PMMA- $Fe_3O_4$  for internal mechanical support and magnetic thermal ablation of bone tumors. *Theranostics* 9 (14), 4192–4207. doi:10.7150/thno.34157

Yu, L., and Ding, J. (2008). Injectable hydrogels as unique biomedical materials. Chem. Soc. Rev. 37 (8), 1473-1481. doi:10.1039/b713009k

Zhang, W., Gu, J., Li, K., Zhao, J., Ma, H., Wu, C., et al. (2019). A hydrogenated black TiO<sub>2</sub> coating with excellent effects for photothermal therapy of bone tumor and bone regeneration. *Mater. Sci. Eng. C* 102, 458–470. doi:10.1016/j.msec.2019. 04.025

Zhang, Y., Wang, F., Li, M., Yu, Z., Qi, R., Ding, J., et al. (2018). Selfstabilized hyaluronate nanogel for intracellular codelivery of doxorubicin and cisplatin to osteosarcoma. *Adv. Sci. (Weinh).* 5 (5), 1700821. doi:10.1002/advs. 201700821

Zhao, P.-P., Ge, Y.-W., Liu, X.-L., Ke, Q.-F., Zhang, J.-W., Zhu, Z.-A., et al. (2020). Ordered arrangement of hydrated  $GdPO_4$  nanorods in magnetic chitosan matrix promotes tumor photothermal therapy and bone regeneration against breast cancer bone metastases. *Chem. Eng. J.* 381, 122694. doi:10.1016/j.cej.2019. 122694

Zou, L., Wang, H., He, B., Zeng, L., Tan, T., Cao, H., et al. (2016). Current approaches of photothermal therapy in treating cancer metastasis with nanotherapeutics. *Theranostics* 6 (6), 762–772. doi:10.7150/thno.14988